Current strategies in prophylaxis and treatment of venous thromboembolism

References

• White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: 14–8
   Web of Science ®Google Scholar
• Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg. 1991; 78: 849–52
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 Suppl: S338–S400
   Google Scholar
• Lu Y, Ma B, Guo R, Wang Y, Zhang J, Wu Y, et al. Deep vein thrombosis in trauma: a prospective study of lower limb orthopedic trauma patients in Tianjin Hospital, China. Int Angiol. 2007; 26: 165–70
   Google Scholar
• Perez JV, Warwick DJ, Case CP, Bannister GC. Death after proximal femoral fracture—an autopsy study. Injury. 1995; 26: 237–40
   Google Scholar
• Lassen MR, Turpie AG, Rosencher N, Borris LC, Ageno W, Lieberman JR, et al. Rivaroxaban—an oral, direct factor Xa inhibitor—for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD 3 Study. J Thromb Haemost 2007; 5: Abstr O-S-006B
   Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178–85
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370: 949–56
   PubMed Web of Science ®Google Scholar
• Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983; 13: 334–6
   PubMed Web of Science ®Google Scholar
• Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med. 1989; 149: 679–81
   PubMedGoogle Scholar
• Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004; 2: 2156–61
   PubMed Web of Science ®Google Scholar
• Sjalander A, Jansson JH, Bergqvist D, Eriksson H, Carlberg B, Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med. 2008; 263: 52–60
   PubMed Web of Science ®Google Scholar
• Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008; 371: 387–94
   PubMed Web of Science ®Google Scholar
• Chopard P, Dorffler-Melly J, Hess U, Wuillemin WA, Hayoz D, Gallino A, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005; 257: 352–7
   PubMed Web of Science ®Google Scholar
• Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352: 969–77
   PubMed Web of Science ®Google Scholar
• Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793–800
   PubMed Web of Science ®Google Scholar
• Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003; 145: 614–21
   PubMed Web of Science ®Google Scholar
• Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996; 26: 49–56
   PubMedGoogle Scholar
• Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006; 332: 325–9
   PubMed Web of Science ®Google Scholar
• Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AGG, et al. Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. J Thromb Haemost. Abstr O-S 2007; 5: 001
   Google Scholar
• Watson, LI, Armon, MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2004:CD002783.
   Google Scholar
• Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. J Thromb Thrombolysis. 1995; 2: 227–9
   PubMedGoogle Scholar
• Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004; 110: 744–9
   PubMed Web of Science ®Google Scholar
• Anderson DR, Levine MN. Thrombolytic therapy for the treatment of acute pulmonary embolism. CMAJ. 1992; 146: 1317–24
   Google Scholar
• Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347: 1143–50
   PubMed Web of Science ®Google Scholar
• van Dongen, CJJ, van der Belt, AGM, Prins, MH, Lensing, AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004:CD001100.
   Google Scholar
• van Dongen, CJ, MacGillavry, MR. Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2005:CD003074.
   Google Scholar
• Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004; 140: 867–73
   PubMed Web of Science ®Google Scholar
• Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003; 349: 1695–702
   PubMed Web of Science ®Google Scholar
• Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med. 1992; 116: 279–84
   PubMed Web of Science ®Google Scholar
• Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006; 296: 935–42
   PubMed Web of Science ®Google Scholar
• Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. A randomized controlled trial. Ann Intern Med. 1993; 119: 874–81
   PubMed Web of Science ®Google Scholar
• Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144: 673–84
   PubMed Web of Science ®Google Scholar
• Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med. 2002; 162: 2605–9
   PubMedGoogle Scholar
• Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost. 2005; 3: 100–2
   PubMed Web of Science ®Google Scholar
• Lee AY. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thromb Res 2007; 120 Suppl 2: S121–7
   Google Scholar
• Doecke CJ, Cosh DG, Gallus AS. Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response. Aust N Z J Med. 1991; 21: 319–24
   PubMedGoogle Scholar
• Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet. 1998; 352: 1505–9
   PubMed Web of Science ®Google Scholar
• Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003; 349: 675–83
   PubMed Web of Science ®Google Scholar
• Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007; 118: 54–61
   Google Scholar
• Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006; 16: 101–10
   PubMed Web of Science ®Google Scholar
• Pinedé L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001; 103: 2453–60
   PubMed Web of Science ®Google Scholar
• Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995; 332: 1661–5
   PubMed Web of Science ®Google Scholar
• Schulman S. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group. Wien Med Wochenschr. 1999; 149: 66–9
   Google Scholar
• Schulman S, Lindmarker P, Holmstrom M, Lärfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006; 4: 734–42
   PubMed Web of Science ®Google Scholar
• Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007; 147: 766–74
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing A, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004; 350: 2257–64
   PubMed Web of Science ®Google Scholar
• Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003; 139: 893–900
   PubMed Web of Science ®Google Scholar
• Aschwanden M, Labs KH, Engel H, Schwob A, Jeanneret C, Mueller-Brand J, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost. 2001; 85: 42–6
   PubMed Web of Science ®Google Scholar
• Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg. 2000; 32: 861–9
   PubMed Web of Science ®Google Scholar
• Schellong SM, Schwarz T, Kropp J, Prescher Y, Beuthien-Baumann B, Daniel WG. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb Haemost. 1999; 82: 127–9
   PubMedGoogle Scholar
• Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997; 349: 759–62
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004; 141: 249–56
   PubMed Web of Science ®Google Scholar
• Cundiff, DK, Manyemba, J, Pezzullo, JC. Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism. Cochrane Database Syst Rev. 2006:CD003746.
   Google Scholar